http://www.igenericdrugs.com Review Rating: 100 out of 100 based on 1742 reviews. 1742 stars
Generic drugs
List of interchangeable brand and generic drugs
compare generic drug prices
 

Cilastatin/Imipenem

Search a suitable generic or branded drugs, if you could not find the prescribed medicine. This site does not supply any medicines. It contains prices for information purposes only.
You should consult a doctor about the dosage before using this medicine!

DRUG NAME:     

 

Cilastatin/Imipenem uses and description

Sort by popularity
Cilastatin/Imipenem - Treatment: The activity of Cilastatin/Imipenem against an unusually broad spectrum of pathogens makes it particularly useful in the treatment of polymicrobic and mixed aerobic/anaerobic infections, as well as initial therapy prior to the identification of the causative organisms. Cilastatin/Imipenem is indicated for the treatment of the following infections due to susceptible organisms: Intra-abdominal, lower respiratory tract, gynecological, septicemia*, genitourinary tract, bone and joint infections, skin and soft tissue infections, endocarditis*. *Not indicated for therapy with the IM formulation. For the treatment of mixed infections caused by susceptible strains of aerobic and anaerobic bacteria. The majority of these mixed infections are associated with contamination by fecal flora or flora originating from the vagina, skin and mouth. In these mixed infections, Bacteroides fragilis is the most commonly encountered anaerobic pathogen and is usually resistant to aminoglycosides, cephalosporins and penicillins. However, Bacteroides fragilis is usually susceptible to Tienam. Cilastatin/Imipenem has demonstrated efficacy against many infections caused by aerobic and anaerobic gram-positive and gram-negative bacteria resistant to the cephalosporins, including cefazolin, cefoperazone, cephalothin, cefoxitin, cefotaxime, moxalactam, cefamandole, ceftazidime and ceftriaxone. Similarly, many infections caused by organisms resistant to aminoglycosides (gentamicin, amikacin, tobramycin) and/or penicillins (ampicillin, carbenicillin, penicillin-G, ticarcillin, piperacillin, azlocillin, mezlocillin) responded to treatment with Tienam. Cilastatin/Imipenem is not indicated for the treatment of meningitis. Prophylaxis: For the prevention of certain postoperative infections in patients undergoing contaminated or potentially contaminated surgical procedures or where the occurrence of postoperative infection could be especially serious.

Treatment: The activity of Cilastatin/Imipenem against an unusually broad spectrum of pathogens makes it particularly useful in the treatment of polymicrobic and mixed aerobic/anaerobic infections, as well as initial therapy prior to the identification of the causative organisms. Treatment of the following infections due to susceptible organisms: Intra-abdominal infections, lower respiratory tract infections, gynecological infections, septicemia, genitourinary tract infections, bone and joint infections, skin and soft tissue infections, endocarditis. Treatment of mixed infections caused by susceptible strains of aerobic and anaerobic bacteria. The majority of these mixed infections are associated with contamination by fecal flora or flora originating from the vagina, skin and mouth. In these mixed infections, Bacteroides fragilis is the most commonly encountered anaerobic pathogen and is usually resistant to aminoglycosides, cephalosporins and penicillins. However, Bacteroides fragilis is usually susceptible to Tienam. Cilastatin/Imipenem has demonstrated efficacy against many infections caused by aerobic and anaerobic gram-positive and gram-negative bacteria resistant to the cephalosporins, including cefazolin, cefoperazone, cephalothin, cefoxitin, cefotaxime, moxalactam, cefamandole, ceftazidime and ceftriaxone. Similarly, many infections caused by organisms resistant to aminoglycosides (gentamicin, amikacin, tobramycin) and/or penicillins (ampicillin, carbenicillin, penicillin-G, ticarcillin, piperacillin, azlocillin, mezlocillin) responded to treatment with Tienam. Cilastatin/Imipenem is not indicated for the treatment of meningitis. Prophylaxis: Prevention of certain postoperative infections in patients undergoing contaminated or potentially contaminated surgical procedures or where the occurrence of postoperative infection could be especially severe.

Treatment: The activity of Cilastatin/Imipenem against an unusually broad spectrum of pathogens makes it particularly useful in the treatment of polymicrobic and mixed aerobic/anaerobic infections, as well as initial therapy prior to the identification of the causative organisms. Cilastatin/Imipenem is indicated for the treatment of the following infections due to susceptible organisms: Intra-abdominal, lower respiratory tract and gynecological infections; septicemia ; genitourinary tract, bone and joint, and skin and soft tissue infections; infective endocarditis. Cilastatin/Imipenem is indicated for the treatment of mixed infections caused by susceptible strains of aerobic and anaerobic bacteria. The majority of these mixed infections are associated with contamination by fecal flora or flora originating from the vagina, skin and mouth. In these mixed infections, Bacteroides fragilis is the most commonly encountered anaerobic pathogen and is usually resistant to aminoglycosides, cephalosporins and penicillins. However, Bacteroides fragilis is usually susceptible to Tienam. Cilastatin/Imipenem has demonstrated efficacy against many infections caused by aerobic and anaerobic gram-positive and gram-negative bacteria resistant to the cephalosporins, including cefazolin, cefoperazone, cephalothin, cefoxitin, cefotaxime, moxalactam, cefamandole, ceftazidime and ceftriaxone. Similarly, many infections caused by organisms resistant to aminoglycosides (gentamicin, amikacin, tobramycin) and/or penicillins (ampicillin, carbenicillin, penicillin-G, ticarcillin, piperacillin, azlocillin, mezlocillin) responded to treatment with Tienam. However, many strains of methicillin-resistant Staphylococci are resistant to imipenem. Cilastatin/Imipenem is not indicated for the treatment of meningitis. Prophylaxis: Cilastatin/Imipenem is also indicated for the prevention of certain postoperative infections in patients undergoing contaminated or potentially contaminated surgical procedures or where the occurrence of postoperative infection could be especially serious.

The activity of Cilastatin/Imipenem against an unusually broad spectrum of pathogens makes it particularly useful in the treatment of polymicrobic and mixed aerobic/anaerobic infections, as well as initial therapy prior to the identification of the causative organisms. Cilastatin/Imipenem is indicated for the treatment of the following infections due to susceptible organisms: Intra-abdominal, lower respiratory tract and gynecological, septicemia, genitourinary tract, bone and joint, and skin and soft tissue infections; and endocarditis. Cilastatin/Imipenem is indicated for the treatment of mixed infections caused by susceptible strains of aerobic and anaerobic bacteria. The majority of these mixed infections are associated with contamination by fecal flora or flora originating from the vagina, skin and mouth. In these mixed infections, Bacteroides fragilis is the most commonly encountered anaerobic pathogen and is usually resistant to aminoglycosides, cephalosporins and penicillins. However, Bacteroides fragilis is usually susceptible to Tienam. Cilastatin/Imipenem has demonstrated efficacy against many infections caused by aerobic and anaerobic gram-positive and -negative bacteria resistant to the cephalosporins, including cefazolin, cefoperazone, cephalothin, cefoxitin, cefotaxime, moxalactam, cefamandole, ceftazidime and ceftriaxone. Similarly, many infections caused by organisms resistant to aminoglycosides (gentamicin, amikacin, tobramycin) and/or penicillins (ampicillin, carbenicillin, penicillin-G, ticarcillin, piperacillin, azlocillin, mezlocillin) responded to treatment with Tienam. Cilastatin/Imipenem is not indicated for the treatment of meningitis. Prophylaxis: Cilastatin/Imipenem is also indicated for the prevention of certain postoperative infections in patients undergoing contaminated or potentially contaminated surgical procedures or where the occurrence of postoperative infection could be especially serious.

Treatment: The activity of Cilastatin/Imipenem against an unusually broad spectrum of pathogens makes it particularly useful in the treatment of polymicrobic and mixed aerobic/anaerobic infections, as well as initial therapy prior to the identification of the causative organisms. Cilastatin/Imipenem is indicated for the treatment of the following infections due to susceptible organisms: Intra-abdominal infections, lower respiratory tract infections, gynecological infections, septicemia, genitourinary tract infections, bone and joint infections, skin and soft tissue infections, endocarditis*. * Not indicated for therapy with the IM formulation. Cilastatin/Imipenem is indicated for the treatment of mixed infections caused by susceptible strains of aerobic and anaerobic bacteria. The majority of these mixed infections are associated with contamination by fecal flora or flora originating from the vagina, skin and mouth. In these mixed infections, Bacteroides fragilis is the most commonly encountered anaerobic pathogen and is usually resistant to aminoglycosides, cephalosporins and penicillins. However, Bacteroides fragilis is usually susceptible to Tienam. Cilastatin/Imipenem has demonstrated efficacy against many infections caused by aerobic and anaerobic gram-positive and gram-negative bacteria resistant to the cephalosporins, including cefazolin, cefoperazone, cephalothin, cefoxitin, cefotaxime, moxalactam, cefamandole, ceftazidime and ceftriaxone. Similarly, many infections caused by organisms resistant to aminoglycosides (gentamicin, amikacin, tobramycin) and/or penicillins (ampicillin, carbenicillin, penicillin-G, ticarcillin, piperacillin, azlocillin, mezlocillin) responded to treatment with Tienam. Cilastatin/Imipenem is not indicated for the treatment of meningitis. Prophylaxis: Cilastatin/Imipenem is also indicated for the prevention of certain postoperative infections in patients undergoing contaminated or potentially contaminated surgical procedures or where the occurrence of postoperative infection could be especially serious.

Indications: bacterial infections

Lower respiratory tract infections, Skin and skin-structure infections, Urinary tract infections, Bacterial septicemia, Bone & joint infections, Gynecologic infections, Intra-abdominal infections, Endocarditis, Polymicrobic infections

Active ingredients: Cilastatin/Imipenem
Unit description, dosagePrice, USD

List of cilastatin/imipenem brand and generic drugs

Chiecool (Japan)
Cilastem (Bulgaria)
Cimispect (India)
Cimispect Imipenem 500mg, Cilastatin500mg VIAL / 1$ 23.15
1's$ 23.15
Cimispect 500+500 Injection$ 0.02
Cimispect 250+250 Injection$ 12.50
Cimispect Imipenem 250 mg, cilastatin250 mg. VIAL / 1$ 12.50
Cimispect Imipenem 500 mg, cilastatin500 mg. VIAL / 1$ 23.15
Cimstan (India)
Cimstan Imipenem 500 mg, Cilastatin500 mg. VIAL / 1$ 26.85
1's$ 26.85
Cimstan 500+500 Injection$ 0.02
Conet (Slovenia)
Dimci (India)
Dimci Imipenem 500 mg, Cilastatin500 mg. VIAL / 1$ 23.33
1's$ 23.33
Dixabiox (Argentina)
Fada Imipenem (Argentina)
Flaminim (India)
Flaminim Imipenem 0.5 g, Cilastatin 0.5g. VIAL / 1$ 23.48
1's$ 23.48
Flaminim 500+500 Injection$ 0.02
Flaminim Imipenem 500mg, Cilastin500mg VIAL / 1$ 23.48
I-NEM (India)
I-Nem Imipenem 250mg, Cilastatin 250mg VIAL / 1$ 12.04
I-Nem Imipenem 500mg, Cilastatin 500mg VIAL / 1$ 24.26
I-Nem Imipenem 250mg, Cilastin250mg VIAL / 1$ 12.04
I-Nem Imipenem 500mg, Cilastin500mg VIAL / 1$ 24.26
1's$ 22.22
Im-Cila
Im-Cila Imipenem 500 mg, Cilastatin500 mg VIAL / 1$ 24.06
Im-Cila Imipenem 250 mg, Cilastatin250 mg. VIAL / 1$ 13.00
Imecitin (Poland)
Imelastin (India)
Imelastin Imipenem 500 mg, Cilastatin500 mg. VIAL / 1$ 29.63
1's$ 29.63
Imelastin 500+500 Injection$ 0.02
Iminem (India)
Iminem Imipenem 250 mg, Cilastatin500 mg VIAL / 1
Iminem Imipenem 500 mg, Cilastatin500 mg. VIAL / 1$ 20.28
1's$ 20.28
Iminem 500+500 Injection$ 15.74
Iminem Imipenem 250 mg, cilastatin500 mg. VIAL / 1
Imipénem Cilastatina Vitalis (Colombia)
Imipénem Cilastatine Kabi (France)
Imipénem Cilastatine Mylan (France)
Imipénem Cilastatine Panpharma (France)
Imipénem Cilastatine Ranbaxy (France)
Imipem (Italy)

Show all Cilastatin/Imipenem generic names
 
Privacy Policy
© 2003 - 2014 igenericdrugs.com All Rights Reserved
 
Disclamer